Lipocomb (Ezetimibe, Rosuvastatin Zinc)

• Lipocomb is indicated for disorders of lipid metabolism where reduction of LDL‑cholesterol is required.
• Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels.
• Mixed dyslipidemia: improves the overall lipid profile by lowering LDL and triglycerides while raising HDL.
• Primary hyperlipidemia: provides combined inhibition of intestinal absorption and hepatic synthesis to achieve target lipid goals.

• Ezetimibe blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter in the intestinal brush‑border, decreasing dietary and biliary cholesterol uptake. Rosuvastatin zinc competitively inhibits HMG‑CoA reductase, the rate‑limiting enzyme of hepatic cholesterol synthesis, leading to up‑regulation of LDL receptors and increased clearance of circulating LDL particles. The dual action produces additive reductions in plasma LDL‑cholesterol.

Lipocomb may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate pain in the head.
• Myalgia: muscle aches without significant weakness.
• Abdominal discomfort: nausea, dyspepsia or flatulence.
• Elevated liver enzymes: mild increase in ALT/AST.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with possible renal impairment.
• Severe hepatic injury: marked elevation of transaminases or jaundice.
• Allergic reactions: rash, angioedema or anaphylaxis.

When prescribing Lipocomb, clinicians should consider several safety and handling points.

• Liver function monitoring: assess baseline transaminases and repeat periodically.
• Renal impairment: adjust use in patients with severe renal dysfunction.
• Drug‑induced myopathy: avoid concomitant strong CYP3A4 inhibitors and monitor CK if muscle symptoms arise.
• Pregnancy and lactation: use only if potential benefit justifies risk, as safety data are limited.
• Alcohol consumption: limit intake to reduce risk of liver toxicity.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Lipocomb can interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase rosuvastatin exposure and risk of myopathy.
• Cyclosporine: raises rosuvastatin plasma levels, increasing toxicity risk.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce ezetimibe absorption; separate administration by at least 2 hours.
• Warfarin: may enhance anticoagulant effect; monitor INR.
• Fibrates (gemfibrozil): increase risk of muscle toxicity; consider dose adjustment.